AVENUE THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
ATXI$0.42-50.7%Stored close · as of Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| For the Years Ended | ||
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(10,488) | $(3,603) |
| Reconciliation of net loss to net cash used in operating activities: | ||
| Share based compensation | 906 | 649 |
| Change in fair value of warrant liability | (4,258) | (5,580) |
| Common shares issuable - Founders Agreement | 371 | 526 |
| Issuance of common stock to Fortress | 72 | — |
| Issuance of common stock for licenses acquired | 1,230 | — |
| Research and development - licenses acquired | 3,000 | — |
| Issuance of subsidiaries’ common shares for license expenses | 6 | 4 |
| Changes in operating assets and liabilities: | ||
| Other receivables - related party | — | 90 |
| Prepaid expenses and other current assets | 70 | (30) |
| Accounts payable and accrued expenses | (662) | 385 |
| Accounts payable and accrued expenses - related party | 302 | (37) |
| Net cash and cash equivalents used in operating activities | (9,451) | (7,596) |
| Cash flows from investing activities: | ||
| Purchase of research and development licenses | (3,000) | — |
| Net cash used in investing activities | (3,000) | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of issuance costs | 7,525 | 11,497 |
| Repurchase of common stock held by InvaGen | — | (1,104) |
| Proceeds from exercise of warrants | 1 | 148 |
| Net cash provided by financing activities | 7,526 | 10,541 |
| Net change in cash and cash equivalents | (4,925) | 2,945 |
| Cash and cash equivalents, beginning of period | 6,708 | 3,763 |
| Cash and cash equivalents, end of period | $1,783 | $6,708 |
| Supplement disclosure of non-cash information: | ||
| Receipt of interest in Baergic from Fortress | $— | $99 |
| Unpaid offering costs | $— | $14 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.